Revenue rose 37% YoY to INR22.5b (our estimate: INR21.3b) in 4QFY18, led by healthy growth in Life Science Ingredients (LSI) and addition of Triad sales. Improved profitability in both Pharma (Ex-Triad) and LSI led to 170bp expansion in the EBITDA margin to20.3% (our estimate: 21%). However, one-time charge due to product development expenditure and higher tax outgo led PAT growth of 3.9% YoY to INR1.5b. Adjusting for the same, PAT stood at INR2.2b (our estimate:INR2.2b).